Windlas Biotech Ltd. (WINDLAS) Price & Analysis

Windlas Biotech Limited functions as a comprehensive contract development and manufacturing organization (CDMO). Its CDMO offerings span the full product lifecycle, encompassing initial discovery, subsequent development, licensing, and large-scale commercial production of various generic pharmaceutical and nutraceutical items. Through these services, it assists clients in bringing both established and innovative pharmaceutical and nutraceutical products to market, which are then sold under the clients' proprietary brand names. Beyond its CDMO segment, Windlas Biotech also develops and manufactures its own portfolio of domestic trade generics and over-the-counter (OTC) brands, catering to the nutritional, ayurvedic, wellness, and personal care sectors. These in-house products reach consumers via a dual distribution approach: traditional offline channels like distributors, stockists, retail pharmacies, and institutional tenders, alongside a robust online presence through various e-commerce platforms. The company's international reach extends through exports, primarily to markets such as Vietnam, Myanmar, Sri Lanka, Thailand, the Philippines, Cambodia, Fiji, Trinidad & Tobago, and South Africa. Established in 2001, Windlas Biotech is headquartered in Gurugram, India.